Watch Iovance Biotherapeutics Inc for free: we tell you when fair value or trend changes.

Iovance Biotherapeutics Inc (IOVA) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Iovance Biotherapeutics Inc stock $5.95, price $8.08, that is 26.4% below the price, quality 39 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

EstimateBear $4.47 to bull $7.44 Growth analysisrevenue history, year by year Quality 39/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

Thin data Nov 11, 2026

Iovance Biotherapeutics Inc

IOVA · US

Expensive, weak quality

Our calculation puts a fair price 26% below what the stock costs today.

Low debt

Positive coverage

Revenue last quarter +80% vs. a year ago.

Mixed Growth (revenue 3y +934.5 %/yr in USD)

Fair value $5.95 · Overvalued

Quality 39/100

Loss-making · -58.2% net margin (TTM)

Negative free cash flow

Trails peers (3/10)

Narrow moat 12/100

Thin data

Estimate

Watch Iovance Biotherapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $1.66 – $27.63 · fair‑value band $4.47 – $7.44 · the $8.08 price screens above the $5.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Iovance Biotherapeutics in your weekly email

Every Wednesday you see whether Iovance Biotherapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.

Show moreShow less

The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.

It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen.

The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.

Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Stock analysis

Iovance Biotherapeutics Inc (IOVA) currently trades at $8.08, while our estimate is $5.95, 26% below the price, so the stock looks overvalued today.

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $4.47 (bear) to $7.44 (bull), the price of $8.08 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Iovance Biotherapeutics Inc reported revenue of $264M in FY2025 versus $0 in FY2021. Reported net income was −$391M in FY2025.

Key figures

Market cap $3.6B Mid · P/S ratio 9.97 · EPS (TTM) $−0.4900 · Net margin −58.2% · Return on equity −29.1% · Return on assets (EBIT) −50.2% (5-year average) · Operating margin −19.7% · Revenue (TTM) $379M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 46% below its 52-week high and 278% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −26%, IOVA screens richer than that median.

Fair Value

Bear $4.47 Fair Value $5.95 Bull $7.44

Price $8.08 · Downside -26.4%

Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13

How much profit the company makes from its sales and capital

Quality Growth 86

Are margins and returns getting better?

Cashflow 6

Do the profits arrive as real cash?

Financial strength 90

Debt, balance sheet and risk of trouble

Investment 42

Does it invest with discipline instead of growing at any price?

Low Volatility 37

How calm the share price moves, does not count

Price momentum 92

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 73

Distance to the 52-week high, does not count

New shares 0

Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 17 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+60.6%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+934.5%

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−167,595.8% (2022) → −153.1% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

IOVA screens overvalued: fair value 26% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (93 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive

Recent news coverage is more positive than average.

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs Yahoo Finance · Nov 6, 2026
Iovance Biotherapeutics Q3 2026 Earnings Preview Seeking Alpha · Nov 4, 2026

Compare Iovance Biotherapeutics Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/9 measures

Overall it trails its industry peers.

Valuation

Quality Score 39 · Below median

Fair Value upside −26.4% · Above median

Profitability

Return on assets −42.8% · Below median

Net margin (12 months) −58.2% · Below median

Operating margin (12 months) −19.7% · Below median

Growth and dividend

Revenue growth (quarter YoY) 80.1% · Top 25%

Balance sheet

Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 5.21× · Pricier than median

P/S (12 months) 9.60× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)100 · sector 0

PAST (return on equity)0 · sector 0

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Regeneron Pharmaceuticals, Inc REGN	$916.06	$1,275	+39%	vs IOVA
Samsung Biologics Co 207940	1,468,000 KRW	1,661,000 KRW	+13%	vs IOVA
Vertex Pharmaceuticals Incorporated VRTX	$547.89	$601.80	+10%	vs IOVA
Genmab A/S GMAB	kr 3,581	kr 3,880	+8%	vs IOVA
argenx SE ARGX	$971.55	$908.40	−7%	vs IOVA
CSL Limited CSL	A$201.68	A$181.40	−10%	vs IOVA
Moderna, Inc MRNA	$250.83	$158.70	−37%	vs IOVA
BeOne Medicines AG 6160	HK$252.20	HK$152.80	−39%	vs IOVA
Celltrion, Inc 068270	203,000 KRW	74,945 KRW	−63%	vs IOVA
Royalty Pharma plc RPRX	$69.45	$19.01	−73%	vs IOVA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks Stocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Iovance Biotherapeutics Inc: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/IOVA?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/IOVA.US.svg" width="360" height="84" alt="Iovance Biotherapeutics Inc: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "Iovance Biotherapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/IOVA

Frequently asked questions

Is Iovance Biotherapeutics Inc (IOVA) overvalued or undervalued?

As of Nov 11, 2026, our estimate of fair value is $5.95 versus a price of $8.08, about 26% lower (overvalued).

What is the fair value of IOVA?

Our estimate for Iovance Biotherapeutics Inc is $5.95 (as of Nov 11, 2026), built from audited fundamentals. The current price: $8.08.

What is the quality score of IOVA?

Iovance Biotherapeutics Inc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Iovance Biotherapeutics Inc (IOVA)?

Our calculated price target is the estimate of $5.95 (as of Nov 11, 2026). Cautious scenario $4.47, optimistic scenario $7.44. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.

What is the Iovance Biotherapeutics Inc stock forecast for 2026?

Our estimate puts fair value at $5.95, about 26% lower versus a price of $8.08 (overvalued). Cautious scenario $4.47, optimistic scenario $7.44. The calculation is refreshed regularly with new filings.

What is the revenue of Iovance Biotherapeutics Inc (IOVA)?

Iovance Biotherapeutics Inc reported trailing-twelve-month revenue of about $379M (latest available figure, as of Nov 11, 2026).

What is the intrinsic value of Iovance Biotherapeutics Inc (IOVA)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Iovance Biotherapeutics Inc it is $5.95 per share (as of Nov 11, 2026), against a price of $8.08.

Is Iovance Biotherapeutics Inc stock overvalued or undervalued in 2026?

As of Nov 11, 2026, IOVA trades above its calculated fair value: price $8.08, fair value $5.95, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of IOVA?

No. The price is what the market pays today ($8.08); the fair value is what the company's own numbers justify ($5.95). For Iovance Biotherapeutics Inc the two are $2.13 per share apart. That gap is exactly why we show both numbers side by side.

How much is Iovance Biotherapeutics Inc worth?

The market values Iovance Biotherapeutics Inc at about $3.6B (market capitalisation, as of Nov 11, 2026). Per share that is $8.08; our models calculate a fair value of $5.95 per share.

What do the bullish and bearish scenarios say about IOVA?

Our models span a range for Iovance Biotherapeutics Inc: cautious scenario $4.47, base $5.95, optimistic $7.44 per share (as of Nov 11, 2026, price $8.08). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Iovance Biotherapeutics Inc (IOVA)?

Balance-sheet figures for Iovance Biotherapeutics Inc (as of Nov 11, 2026): return on equity −29.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.

How far is IOVA from its 52-week high?

Iovance Biotherapeutics Inc trades at $8.08, about 46% below its 52-week high of $14.86 and 278% above the low of $2.14 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $5.95 is for.

Which stocks are comparable to Iovance Biotherapeutics Inc?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Iovance Biotherapeutics Inc stock attractive at the current price?

The data as of Nov 11, 2026: price $8.08, calculated fair value $5.95 (−26%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

Is it still worth investing in stocks now?

The global stock market currently sits 15.1% above its aggregate fair value. Iovance Biotherapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Iovance Biotherapeutics Inc (IOVA)?

The closing price on Nov 10, 2026 was $8.08. Our estimate is $5.95, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Iovance Biotherapeutics Inc right now?

The price sits above even our optimistic bull case ($7.44). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Iovance Biotherapeutics Inc

How large is the market capitalisation of Iovance Biotherapeutics Inc (IOVA)?

The market capitalisation of Iovance Biotherapeutics Inc is $3.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Iovance Biotherapeutics Inc (IOVA)?

The price-to-sales ratio of Iovance Biotherapeutics Inc is 9.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Iovance Biotherapeutics Inc (IOVA)?

Earnings per share at Iovance Biotherapeutics Inc are $−0.4900. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Iovance Biotherapeutics Inc (IOVA)?

The net margin of Iovance Biotherapeutics Inc is −58.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Iovance Biotherapeutics Inc (IOVA)?

The return on equity (ROE) of Iovance Biotherapeutics Inc is −29.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Iovance Biotherapeutics Inc (IOVA)?

On an EBIT basis the return on assets of Iovance Biotherapeutics Inc is −50.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Iovance Biotherapeutics Inc (IOVA)?

The operating margin of Iovance Biotherapeutics Inc is −19.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Iovance Biotherapeutics Inc (IOVA)?

Revenue at Iovance Biotherapeutics Inc is growing +80.1% versus a year earlier (3y avg +935%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Iovance Biotherapeutics Inc (IOVA) generate?

The free cash flow of Iovance Biotherapeutics Inc is −$336M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Iovance Biotherapeutics Inc (IOVA) hold?

Iovance Biotherapeutics Inc holds more cash than debt, $115M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Iovance Biotherapeutics Inc in the live analysis

One click puts Iovance Biotherapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.